There is strong evidence from randomised cardiovascular outcome trials (CVOTs) that several long-acting GLP-1 RAs (liraglutide, dulaglutide and subcutaneous semaglutide) provide cardiovascular protection to individuals with T2D with pre-existing cardiovascular disease (secondary prevention) or at high risk of CV events, and to a lesser extent those without overt atherosclerotic vascular disease (primary prevention

Managing combined side effects Expect amplified GI effects: Both peptides slow gastric emptying Synergistic nausea (not just additive) Constipation very common Weeks 9-16 most challenging Nausea management protocol: Prevention from day 1 (ginger, small meals) Prescription anti-nausea (Zofran) essential Liquid nutrition if needed Slower titration if poorly tolerated Constipation prevention: 80-100 oz water daily Fiber 25-30g daily Magnesium citrate 300-500mg nightly MiraLAX as needed Nutrition maintenance: Protein shakes 2-3 daily (30-40g each) Target 60-80g protein minimum Multivitamin daily B12 supplementation When to reduce doses: Severe persistent nausea despite management Unable to maintain adequate nutrition Vomiting frequently Quality of life severely impacted See our common peptide mistakes beginners make to avoid errors
its the median
Dose reduction or a slower titration schedule can restore energy balance without sacrificing weight loss results
The plasma half-life is approximately 2.5 hours, but the neurochemical effects persist longer
Meet Your Synergistic Healing Partners: BPC-157 and TB-500 BPC-157 is derived from a body protection compound found in human gastric juice, famous for speeding up muscle, tendon, and ligament healing